Olympus (FRA:OLY1) Beneish M-Score: -2.38 (As of Jun. 27, 2026)


FRA:OLY1 Olympus Corp FRA:OLY1
82 GF Score
Price €9.06
GF Value €13.88
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Olympus Beneish M-Score?

Olympus FRA:OLY1 +3.45% 82 Beneish M-Score is -2.38 as of Jun. 27, 2026. GuruFocus rates FRA:OLY1 with a GF Score™ of 82/100 and a GF Value™ of €13.88 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Olympus ranks worse than 65.8% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.38 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Olympus's Beneish M-Score or its related term are showing as below:

FRA:OLY1' s Beneish M-Score Range Over the Past 10 Years
Min: -3   Med: -2.63   Max: -1.76
Current: -2.38

During the past 13 years, the highest Beneish M-Score of Olympus was -1.76. The lowest was -3.00. And the median was -2.63.


Olympus Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Olympus's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Olympus Beneish M-Score Chart

Olympus Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.57 -2.27 -1.76 -2.62 -2.38

Olympus Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.62 -2.63 -2.36 -2.54 -2.38

FRA:OLY1 vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Olympus's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Olympus Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Olympus's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Olympus's Beneish M-Score falls into.


FRA:OLY1
82GF Score
Olympus Corp FRA:OLY1
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Olympus Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Olympus for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0958+0.528 * 1.0594+0.404 * 1.0337+0.892 * 0.9298+0.115 * 1.0218
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0128+4.679 * -0.020172-0.327 * 0.9942
=-2.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €1,291 Mil.
Revenue was 1609.615 + 1429.833 + 1428.066 + 1239.214 = €5,707 Mil.
Gross Profit was 1050.754 + 903.208 + 929.443 + 810.867 = €3,694 Mil.
Total Current Assets was €3,850 Mil.
Total Assets was €8,379 Mil.
Property, Plant and Equipment(Net PPE) was €1,566 Mil.
Depreciation, Depletion and Amortization(DDA) was €381 Mil.
Selling, General, & Admin. Expense(SGA) was €2,872 Mil.
Total Current Liabilities was €2,381 Mil.
Long-Term Debt & Capital Lease Obligation was €871 Mil.
Net Income was 135.27 + 77.614 + 116.371 + 53.952 = €383 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = €0 Mil.
Cash Flow from Operations was 224.859 + 209.591 + 209.008 + -91.228 = €552 Mil.
Total Receivables was €1,267 Mil.
Revenue was 1688.627 + 1559.597 + 1507.663 + 1381.913 = €6,138 Mil.
Gross Profit was 1196.214 + 1042.946 + 1050.98 + 919.266 = €4,209 Mil.
Total Current Assets was €4,217 Mil.
Total Assets was €8,894 Mil.
Property, Plant and Equipment(Net PPE) was €1,634 Mil.
Depreciation, Depletion and Amortization(DDA) was €408 Mil.
Selling, General, & Admin. Expense(SGA) was €3,050 Mil.
Total Current Liabilities was €2,640 Mil.
Long-Term Debt & Capital Lease Obligation was €832 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1291.007 / 5706.728) / (1267.089 / 6137.8)
=0.226225 / 0.20644
=1.0958

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(4209.406 / 6137.8) / (3694.272 / 5706.728)
=0.685817 / 0.647354
=1.0594

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3850.177 + 1565.614) / 8379.27) / (1 - (4217.102 + 1634.197) / 8894.397)
=0.353668 / 0.342137
=1.0337

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=5706.728 / 6137.8
=0.9298

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(408.486 / (408.486 + 1634.197)) / (380.982 / (380.982 + 1565.614))
=0.199975 / 0.195717
=1.0218

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2871.887 / 5706.728) / (3049.7 / 6137.8)
=0.503246 / 0.496872
=1.0128

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((870.545 + 2381.457) / 8379.27) / ((832.284 + 2639.675) / 8894.397)
=0.388101 / 0.390354
=0.9942

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(383.207 - 0 - 552.23) / 8379.27
=-0.020172

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Olympus has a M-score of -2.50 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.38 mean?
Olympus (FRA:OLY1) has a Beneish M-Score of -2.38 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Olympus and its competitors. According to the industry distribution chart, Olympus ranks #504 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 65.8%.
Is Olympus' Beneish M-Score too high?
Olympus' current Beneish M-Score is -2.38. Based on the distribution chart, Olympus ranks #504 out of 766 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Olympus has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Olympus' Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Olympus ranks #504 out of 766 companies for Beneish M-Score. This places Olympus in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Olympus and its competitors. Olympus's current Beneish M-Score is -2.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Olympus stock overvalued right now?
Based on GuruFocus' analysis, Olympus (FRA:OLY1) is currently considered Significantly Undervalued. The stock's GF Value™ is €13.88, compared to a current price of €9.06 — trading 34.8% below its estimated fair value. The current Beneish M-Score is -2.38. Olympus' overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Olympus (FRA:OLY1), the current Beneish M-Score is -2.38 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Olympus (FRA:OLY1) Overvalued in 2026?

Based on GuruFocus' analysis, Olympus stock appears to be undervalued. The current stock price of €9.06 is trading 34.8% below its estimated GF Value™ of €13.88. GuruFocus considers Olympus to be Significantly Undervalued.

Key valuation signals for FRA:OLY1:

  • Beneish M-Score: -2.38
  • GF Value™: €13.88 vs. price of €9.06 (34.8% below fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the FRA:OLY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Olympus Business Description

Address 2951 Ishikawacho, Hachioji, JPN, 192-8507
Olympus is a medical-device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2025, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.
82GF Score

Get the complete analysis for FRA:OLY1

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.06
Price
€13.88
GF Value